The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa's financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval SERB has a substantial...
Hence then, the article about hansa biopharma enters into 115 million licensing agreement with serb pharmaceuticals for idefirix in europe and mena was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA )
Also on site :
- French President Emmanuel Macron Calls on YouTube to Finance Content and Warns of Growing Threat to Cultural Model (EXCLUSIVE)
- President Trump Posts Photo of Hollywood Icon Who Has Slammed Him for Years: ‘Even This Jerk Is Beginning to Get It’
- 2005 Coldplay Hit, Written by All Four Band Members, Considered ‘One of the Greatest Songs of All Time’